Unibest 优贝德
Login / Register

APIs Recommended for You

Three inputs drive the ranking: the region of your target market, the indication classes you follow, and each molecule's patent-expiry window. Every card states why it was picked.

What drives these picks

Region
全球

按通用需求排序，可自行切换目标市场

Indications you follow
—

No interests selected yet — tick a few below and the list updates immediately.

Visitor region (by IP)
全球fallback

未识别到访客区域，展示全量热门品种；选定目标国后可查看对应注册路径

Which therapeutic areas do you follow?

Multi-select, change any time
Metabolic / EndocrineCardiovascular / RenalOncology / HematologyAnti-infectivesImmunology / InflammationCNS / PsychiatryGastroenterology / HepatologyRespiratoryUrology / Women's HealthOphthalmologyDermatologyAnesthesia / AnalgesiaAllergyAnimal Health

Sign in and we remember your market and interests — you land straight on this page next time.

Anti-infectivesOff-patent · 2026 (indicative)4 intermediates
Letermovir

Prophylaxis of cytomegalovirus (CMV) infection in adult recipients of allogeneic hematopoietic stem cell transplant

Why it was picked
  • · 全球需求旺盛类目（+30）
  • · 已到期（+25）
  • · 已商业化可供（+10）
  • · 已收录关键中间体，可沿供应链往下采购（+15）
  • · GMP / DMF 就绪（+4）
View intermediates →
Metabolic / EndocrineOff-patent · 2026 (indicative)3 intermediates
Semaglutide

Glycemic control in type 2 diabetes and weight management; reduces cardiovascular risk

Why it was picked
  • · 全球需求旺盛类目（+30）
  • · 已到期（+25）
  • · 已商业化可供（+10）
  • · 已收录关键中间体，可沿供应链往下采购（+15）
  • · GMP / DMF 就绪（+4）
View intermediates →
Anti-infectivesExpiring in 3-5 yrs · 2031 (indicative)4 intermediates
Baloxavir Marboxil

Single-dose oral treatment and post-exposure prophylaxis of influenza A and B

Why it was picked
  • · 全球需求旺盛类目（+30）
  • · 3-5 年内到期（+12）
  • · 已商业化可供（+10）
  • · 已收录关键中间体，可沿供应链往下采购（+15）
  • · GMP / DMF 就绪（+4）
View intermediates →
Cardiovascular / RenalOff-patent · 1995
Methyldopa hydrate

Treatment of hypertension, especially pregnancy-induced hypertension

Why it was picked
  • · 全球需求旺盛类目（+30）
  • · 已到期（+25）
  • · 已商业化可供（+10）
  • · GMP / DMF 就绪（+4）
Methyldopa hydrate →
Cardiovascular / RenalExpiring within 2 yrs · 2027 (indicative)
Edoxaban

Stroke prevention in non-valvular atrial fibrillation; treatment of DVT and pulmonary embolism

Why it was picked
  • · 全球需求旺盛类目（+30）
  • · 2 年内到期（+20）
  • · 已商业化可供（+10）
  • · GMP / DMF 就绪（+4）
Edoxaban →
Anti-infectivesExpiring within 2 yrs · 2027 (indicative)
Isavuconazole

Invasive aspergillosis and mucormycosis (deep fungal infections)

Why it was picked
  • · 全球需求旺盛类目（+30）
  • · 2 年内到期（+20）
  • · 已商业化可供（+10）
  • · GMP / DMF 就绪（+4）
Isavuconazole →
Cardiovascular / RenalTo be assessed6 intermediates
Finerenone

Chronic kidney disease (CKD) associated with type 2 diabetes; slows renal function decline and cardiovascular events

Why it was picked
  • · 全球需求旺盛类目（+30）
  • · 待评估（+2）
  • · 已商业化可供（+10）
  • · 已收录关键中间体，可沿供应链往下采购（+15）
  • · GMP / DMF 就绪（+4）
View intermediates →
Metabolic / EndocrineTo be assessed23 intermediates
Orforglipron

Oral treatment of type 2 diabetes and obesity

Why it was picked
  • · 全球需求旺盛类目（+30）
  • · 待评估（+2）
  • · 已商业化可供（+10）
  • · 已收录关键中间体，可沿供应链往下采购（+15）
  • · GMP / DMF 就绪（+4）
View intermediates →
Anti-infectivesTo be assessed3 intermediates
Ozenoxacin

Topical treatment of superficial skin bacterial infections such as impetigo

Why it was picked
  • · 全球需求旺盛类目（+30）
  • · 待评估（+2）
  • · 已商业化可供（+10）
  • · 已收录关键中间体，可沿供应链往下采购（+15）
  • · GMP / DMF 就绪（+4）
View intermediates →
Anti-infectivesOff-patent · 2012
Abacavir hydroxyacetate

Antiretroviral combination therapy for HIV-1 infection

Why it was picked
  • · 全球需求旺盛类目（+30）
  • · 已到期（+25）
  • · GMP / DMF 就绪（+4）
Abacavir hydroxyacetate →
Metabolic / EndocrineOff-patent · 2025 (indicative)
Dapagliflozin Propanediol Monohydrate

Glycemic control in type 2 diabetes; reduces heart-failure hospitalization and slows chronic kidney disease progression

Why it was picked
  • · 全球需求旺盛类目（+30）
  • · 已到期（+25）
  • · GMP / DMF 就绪（+4）
Dapagliflozin Propanediol Monohydrate →
Cardiovascular / RenalTo be assessed
Iptacopan

Paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy and C3 glomerulopathy

Why it was picked
  • · 全球需求旺盛类目（+30）
  • · 待评估（+2）
  • · 已商业化可供（+10）
  • · GMP / DMF 就绪（+4）
Iptacopan →

Patent expiry compiled from public sources and indicative only; defer to national patent offices and the Orange Book.